Theravance initiates Phase 2b study with TD-4208 Theravance announced the initiation of a dose ranging Phase 2b study with TD-4208 as a nebulized aqueous solution in patients with moderate to severe COPD. TD-4208 is an investigational inhaled long-acting muscarinic antagonist, discovered using Theravance's multivalent approach to drug design. This compound is under development by Theravance for the treatment of chronic obstructive pulmonary disease, or COPD.
News For THRX From The Last 14 Days
Check below for free stories on THRX the last two weeks.